ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million
21 Oct, 2021
– Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics as vaccines and therapeutics for the world’s most debilitating diseases, today announced the completion of an oversubscribed $230 million Series C financing.
– This financing round brings Clover’s total capital raised in the last 12 months to over $400 million (over RMB 2.5 billion).
– The Series C round was co-led by GL Ventures and Temasek, with participation from Oceanpine Capital, OrbiMed and existing investor Delos Capital.
– The proceeds will support the continued development and expansion of Clover’s pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag© technology platform.